Switch theme
Sign up to access all valuation multiples
Alkaloid AD Skopje is engaged in producing and selling pharmaceutical, chemical and cosmetic products, as well as goods from the herbal origin. Its segments are Pharmaceuticals, Chemicals, Cosmetics and Botanicals.
1936
2.0K+
LTM Revenue n/a
LTM EBITDA n/a
$709M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Alkaloid has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Alkaloid achieved revenue of $334M and an EBITDA of $52.9M.
Alkaloid expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Alkaloid valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $290M | $334M | XXX | XXX | XXX |
| Gross Profit | $114M | $133M | XXX | XXX | XXX |
| Gross Margin | 39% | 40% | XXX | XXX | XXX |
| EBITDA | $32.1M | $52.9M | XXX | XXX | XXX |
| EBITDA Margin | 11% | 16% | XXX | XXX | XXX |
| Net Profit | $25.7M | $27.7M | XXX | XXX | XXX |
| Net Margin | 9% | 8% | XXX | XXX | XXX |
| Net Debt | $21.1M | $24.7M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Alkaloid's stock price is MKD 27350 (or $481).
Alkaloid has current market cap of MKD 38.5B (or $678M), and EV of MKD 40.3B (or $709M).
See Alkaloid trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $709M | $678M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Alkaloid has market cap of $678M and EV of $709M.
Alkaloid's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Alkaloid's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Alkaloid and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $709M | XXX | XXX | XXX |
| EV/Revenue | 2.1x | XXX | XXX | XXX |
| EV/EBITDA | 13.4x | XXX | XXX | XXX |
| P/E | 22.9x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 89.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAlkaloid's NTM/LTM revenue growth is n/a
Alkaloid's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Alkaloid's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Alkaloid's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Alkaloid and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 15% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 16% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 65% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 29% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 4% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| Opex to Revenue | 31% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Alkaloid acquired XXX companies to date.
Last acquisition by Alkaloid was XXXXXXXX, XXXXX XXXXX XXXXXX . Alkaloid acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Alkaloid founded? | Alkaloid was founded in 1936. |
| Where is Alkaloid headquartered? | Alkaloid is headquartered in Macedonia. |
| How many employees does Alkaloid have? | As of today, Alkaloid has 2.0K+ employees. |
| Is Alkaloid publicy listed? | Yes, Alkaloid is a public company listed on MAE. |
| What is the stock symbol of Alkaloid? | Alkaloid trades under ALK ticker. |
| Who are competitors of Alkaloid? | Similar companies to Alkaloid include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Alkaloid? | Alkaloid's current market cap is $678M |
| What is the current revenue growth of Alkaloid? | Alkaloid revenue growth between 2023 and 2024 was 15%. |
| Is Alkaloid profitable? | Yes, Alkaloid is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
